Who owns Rapport Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of RAPP from SEC Form 13F filings across 160 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 160 institutions disclosed 51.3M shares of Rapport Therapeutics, Inc. worth $2.13B — about 108% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
160
13F holders
$2.13B
value, 2026 filers
108%
of shares outstanding (51.3M sh)
28
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of RAPP's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 7.2M | $298.9M | 0.0% | 15.1% | +0.1% |
| 2 | TRV GP V, LLC | 6.3M | $261.7M | 52.5% | 13.2% | -12.0% |
| 3 | ARCH Venture Management, LLC | 3.7M | $155.4M | 14.1% | 7.9% | 0.0% |
| 4 | Capital International Investors | 2.9M | $121.8M | 0.0% | 6.2% | -5.7% |
| 5 | GOLDMAN SACHS GROUP INC | 2.9M | $121.3M | 0.0% | 6.1% | -1.1% |
| 6 | BlackRock, Inc. | 2.7M | $112.5M | 0.0% | 5.7% | +7.7% |
| 7 | Cormorant Asset Management, LP | 2.7M | $110.7M | 5.7% | 5.6% | -10.1% |
| 8 | Sofinnova Investments, Inc. | 1.9M | $79.4M | 4.1% | 4% | 0.0% |
| 9 | JOHNSON & JOHNSON | 1.8M | $74.4M | 9.3% | 3.8% | 0.0% |
| 10 | Polar Capital Holdings Plc | 1.6M | $67.0M | 0.2% | 3.4% | -2.1% |
| 11 | BAKER BROS. ADVISORS LP | 1.5M | $64.5M | 0.3% | 3.3% | 0.0% |
| 12 | VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $56.1M | 0.0% | 2.8% | +1.6% |
| 13 | TRV GP VI, LLC | 969,218 | $40.4M | 17.4% | 2% | 0.0% |
| 14 | STATE STREET CORP | 818,712 | $34.1M | 0.0% | 1.7% | +7.8% |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 793,453 | $33.1M | 0.0% | 1.7% | +10.0% |
| 16 | PRICE T ROWE ASSOCIATES INC /MD/ | 787,446 | $32.8M | 0.0% | 1.7% | -9.1% |
| 17 | PERCEPTIVE ADVISORS LLC | 773,342 | $32.2M | 0.5% | 1.6% | +14.8% |
| 18 | Vestal Point Capital, LP | 730,000 | $30.4M | 0.7% | 1.5% | -49.2% |
| 19 | ALLIANCEBERNSTEIN L.P. | 693,384 | $21.7M | 0.0% | 1.5% | -4.7% |
| 20 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 644,082 | $26.8M | 0.0% | 1.4% | -29.9% |
| 21 | Siren, L.L.C. | 641,469 | $26.7M | 0.5% | 1.4% | 0.0% |
| 22 | Capital World Investors | 551,657 | $23.0M | 0.0% | 1.2% | +2.8% |
| 23 | T. Rowe Price Investment Management, Inc. | 393,200 | $16.4M | 0.0% | 0.8% | -36.6% |
| 24 | DIMENSIONAL FUND ADVISORS LP | 362,114 | $15.1M | 0.0% | 0.8% | +61.3% |
| 25 | VANGUARD PORTFOLIO MANAGEMENT LLC | 359,944 | $15.0M | 0.0% | 0.8% | +12.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.